메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

AIM's Iterative Process High-Efficiency Diploid Rabies Vaccine Completes Phase III Clinical Trials, Efficacy Significantly Higher than Existing Market Products

HONG KONG, Jan. 15, 2026 -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 15 that its research and development of the iterative process high-efficiency diploid rabies vaccine has successfully completed the Phase III clinical site work. This marks the official entry of the vaccine into a new phase, laying a solid foundation for future commercialization. At this critical juncture where the vaccine industry is shifting from "scale expansion" to "value competition," AIM's iterative rabies vaccine will provide strong support for the company's
- 김갑성 기자
- 2026-01-15 08:30
Heartstream Launched as Independent Emergency Care Company

Former Philips Emergency Care business becomes first platform company of Emergency Care Holdings, advancing a century-long mission to save lives BOTHELL, Wash., Jan. 15, 2026 -- Emergency Care Holdings (ECH), a platform formed by Bridgefield Capital to assemble and grow category-leading companies in the emergency medical products sectors, announced the debut of Heartstream today, a new independent company dedicated to advancing life-saving emergency care technologies. Heartstream is formed through ECH's completed acquisition of the Philips Emergency Care business from Ro
- 김갑성 기자
- 2026-01-15 00:45
Metabolon Appoints Celia Reyes as Vice President of Human Resources

Celia Reyes will lead Metabolon's global people strategy as the company continues to scale in the evolving multiomics marketplace MORRISVILLE, N.C., Jan. 14, 2026 -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces the appointment of Celia Reyes as Vice President of Human Resources. "We are delighted to welcome Celia to the Metabolon leadership team," said Rohan Hastie, Ph.D., President and CEO of Metabolon
- 김갑성 기자
- 2026-01-14 22:00
Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion

SEOUL, South Korea, Jan. 14, 2026 -- Yuyu Bio and Mervyn's Petcare, pet-focused subsidiaries of Yuyu Pharma, have opened a new office on the UCLA campus, strengthening the company's presence in the United States pet and animal health market. The two companies are now based at Magnify, the startup incubator housed within the California NanoSystems Institute (CNSI) at UCLA. Magnify provides office space, meeting facilities, and access to a dynamic innovation ecosystem. The new office will serve as Yuyu Pharma's North American base for pet-related ventures, enabling
- 김갑성 기자
- 2026-01-14 22:00
NYSE Content Advisory: Pre-Market Update + Inaugural U.S.-Saudi Biotech Alliance Summit Begins in SF

NEW YORK, Jan. 14, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Inaugural U.S.-Saudi Biotech Alliance Summit Begins in SF Kristen Scholer delivers the pre-market update on January 14th U.S. equities traded fractionally lower pre-market as investors digest a packed agenda, including earnings from major banks, speeches from several Fed officials, key economic data,
- 김갑성 기자
- 2026-01-14 21:55
iotaMotion Receives FDA Clearance for Expanded Pediatric Use of iotaSOFT® Robotic-Assisted Cochlear Implant Insertion System

ST. PAUL, Minn., Jan. 14, 2026 -- iotaMotion, Inc., creator of iotaSOFT®, the first and only FDA cleared robotic-assisted cochlear implant insertion system, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for expanded pediatric use of its iotaSOFT® Insertion System. The system is now cleared for use in patients four years of age and older, extending access to robotic-assisted cochlear implantation for school-aged children. "Receiving FDA clearance for expanded pediatric use marks a significant milestone for iotaMotion and for families navi
- 김갑성 기자
- 2026-01-14 21:03
Lynx Analytics Introduces Lumen, an Agentic AI Framework to Improve Decision-Making in Life Sciences

LOS GATOS, Calif., Jan. 14, 2026 -- Lynx Analytics today announced Lumen, a specialized Agentic AI framework designed to help pharmaceutical and biotech organizations generate strategic, decision-ready insights from complex scientific and commercial information. Built specifically for life sciences workflows, Lumen enables companies to deploy AI agents across a wide range of real-world use cases — from rapidly distilling lengthy clinical or market research documents, to generating dynamic HCP personas and personalized engagement strategies, to powering natural-lan
- 김갑성 기자
- 2026-01-14 21:00
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

HONG KONG, Jan. 14, 2026 -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for the first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS <5 (a propensity-matched, retrospective cohort study). The study results showed that the cadonilimab regimen, compared to the PD-1 monoclonal antibody regimen, significantly prolonged patients' o
- 김갑성 기자
- 2026-01-14 11:54
Enhanced Genetype colorectal cancer risk test released - supports earlier disease detection and ColoSTAT® targeting

MELBOURNE, Australia, Jan. 14, 2026 -- Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce the commercial launch of its updated geneTypeTM Colorectal Cancer (CRC) Risk Assessment clinical test ("geneTypeTM CRC"), a significant advancement in personalised cancer risk prediction. The updated test incorporates additional clinical and lifestyle risk factors alongside the established 140-SNP polygenic risk score (PRS), delivering improved predictive accuracy across both
- 김갑성 기자
- 2026-01-14 11:40
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

Celltrion outlines a blueprint for innovative drug development built on its antibody expertise The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and operations INCHEON, South Korea, Jan. 14, 2026 -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today presented key strategic priorities and clinical development updates for its innovative drug pipelines including antibody-drug conjugates (ADCs) and multi-specific antibodies (msAbs) at the 44th Annual
- 김갑성 기자
- 2026-01-14 09:18

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2026-03-03_TUE

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 03시 40분